Dicerna Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that are designed to utilize ribonucleic acid interference to silence selectively genes that cause or contribute to disease. Nedosiran is Co.'s investigational product candidate for the treatment of primary hyperoxaluria (PH) type 1, PH type 2, and PH type 3. Co.'s GalXC product candidate, RG6346, is for the treatment of chronic hepatitis B virus (HBV) infection. Therapies for HBV include nucleoside analogs and pegylated interferon regimens. Co.'s another GalXC product candidate, belcesiran, is for the treatment of alpha-1 antitrypsin deficiency-associated liver disease. The DRNA stock yearly return is shown above.
The yearly return on the DRNA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the DRNA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|